Allergan, Inc. (NYSE: AGN) acquired EndoArt S.A., Swiss medical technology developer , a leader in the field of telemetrically-controlled (or remote-controlled) implants used in the treatment of morbid obesity and other conditions. The acquisition builds upon the strength of Allergan’s existing obesity intervention product portfolio, which includes the LAP-BAND® Adjustable Gastric Banding System, currently the only adjustable implant device for individualized weight loss approved in the United States and a leading bariatric procedure worldwide; and the BIBTM Intragastric Balloon System, a non-surgical alternative for the treatment of obesity approved in many countries although not currently available in the United States.